Aldehyde dehydrogenase inhibitor - Haim Bio
Latest Information Update: 28 Mar 2025
At a glance
- Originator Haim Bio Co
- Class
- Mechanism of Action Aldehyde dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lactic acidosis
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for preclinical development in Lactic-acidosis in South Korea
- 09 Feb 2021 Preclinical trials in Lactic acidosis in South Korea (unspecified route) before February 2021 (Haim Bio pipeline, February 2021)
- 04 Jun 2019 Haim has patent protection for aldehyde dehydrogenase inhibitor